Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.09
HOLX's Cash to Debt is ranked lower than
95% of the 202 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.69 vs. HOLX: 0.09 )
Ranked among companies with meaningful Cash to Debt only.
HOLX' s Cash to Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.87 Max: No Debt
Current: 0.09
Equity to Asset 0.28
HOLX's Equity to Asset is ranked lower than
88% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.62 vs. HOLX: 0.28 )
Ranked among companies with meaningful Equity to Asset only.
HOLX' s Equity to Asset Range Over the Past 10 Years
Min: 0.22  Med: 0.67 Max: 0.88
Current: 0.28
0.22
0.88
Interest Coverage 2.77
HOLX's Interest Coverage is ranked lower than
88% of the 129 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.81 vs. HOLX: 2.77 )
Ranked among companies with meaningful Interest Coverage only.
HOLX' s Interest Coverage Range Over the Past 10 Years
Min: 0.55  Med: 2.21 Max: 71.1
Current: 2.77
0.55
71.1
F-Score: 7
Z-Score: 1.08
M-Score: -2.75
WACC vs ROIC
6.04%
7.48%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 18.09
HOLX's Operating margin (%) is ranked higher than
83% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.55 vs. HOLX: 18.09 )
Ranked among companies with meaningful Operating margin (%) only.
HOLX' s Operating margin (%) Range Over the Past 10 Years
Min: -123.18  Med: 8.28 Max: 20.93
Current: 18.09
-123.18
20.93
Net-margin (%) 7.48
HOLX's Net-margin (%) is ranked higher than
64% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.86 vs. HOLX: 7.48 )
Ranked among companies with meaningful Net-margin (%) only.
HOLX' s Net-margin (%) Range Over the Past 10 Years
Min: -132.93  Med: -1.50 Max: 12.81
Current: 7.48
-132.93
12.81
ROE (%) 9.74
HOLX's ROE (%) is ranked higher than
66% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.62 vs. HOLX: 9.74 )
Ranked among companies with meaningful ROE (%) only.
HOLX' s ROE (%) Range Over the Past 10 Years
Min: -59.07  Med: -0.73 Max: 13.4
Current: 9.74
-59.07
13.4
ROA (%) 2.68
HOLX's ROA (%) is ranked higher than
54% of the 204 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.86 vs. HOLX: 2.68 )
Ranked among companies with meaningful ROA (%) only.
HOLX' s ROA (%) Range Over the Past 10 Years
Min: -31.5  Med: -0.35 Max: 9.84
Current: 2.68
-31.5
9.84
ROC (Joel Greenblatt) (%) 66.61
HOLX's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 200 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.41 vs. HOLX: 66.61 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
HOLX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -369.68  Med: 25.23 Max: 90.76
Current: 66.61
-369.68
90.76
Revenue Growth (3Y)(%) 7.20
HOLX's Revenue Growth (3Y)(%) is ranked higher than
60% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. HOLX: 7.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
HOLX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -7.8  Med: 10.30 Max: 35.9
Current: 7.2
-7.8
35.9
EBITDA Growth (3Y)(%) 23.40
HOLX's EBITDA Growth (3Y)(%) is ranked higher than
78% of the 138 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.90 vs. HOLX: 23.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
HOLX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -5.1  Med: 37.85 Max: 89.6
Current: 23.4
-5.1
89.6
» HOLX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-29)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

HOLX Guru Trades in Q2 2015

RS Investment Management 549,790 sh (New)
Prem Watsa 20,000 sh (unchged)
Vanguard Health Care Fund 7,379,300 sh (unchged)
Carl Icahn 34,154,879 sh (unchged)
Ken Fisher 128,300 sh (unchged)
Paul Tudor Jones Sold Out
Kahn Brothers 1,359,812 sh (-1.31%)
Murray Stahl 24,370 sh (-6.80%)
Jim Simons 174,400 sh (-88.38%)
» More
Q3 2015

HOLX Guru Trades in Q3 2015

Paul Tudor Jones 20,500 sh (New)
Steven Cohen 237,500 sh (New)
Joel Greenblatt 561,229 sh (New)
Pioneer Investments 21,974 sh (New)
RS Investment Management 921,560 sh (+67.62%)
Prem Watsa 20,000 sh (unchged)
Jim Simons Sold Out
Kahn Brothers 1,342,012 sh (-1.31%)
Vanguard Health Care Fund 6,159,700 sh (-16.53%)
Carl Icahn 28,154,879 sh (-17.57%)
Murray Stahl 17,042 sh (-30.07%)
Ken Fisher 47,632 sh (-62.87%)
» More
Q4 2015

HOLX Guru Trades in Q4 2015

Jim Simons 1,667,118 sh (New)
Pioneer Investments 147,180 sh (+569.79%)
Steven Cohen 998,300 sh (+320.34%)
RS Investment Management 1,142,810 sh (+24.01%)
Kahn Brothers 1,350,251 sh (+0.61%)
Carl Icahn 28,154,879 sh (unchged)
Paul Tudor Jones Sold Out
Prem Watsa Sold Out
Ken Fisher 47,600 sh (-0.07%)
Vanguard Health Care Fund 5,802,700 sh (-5.80%)
Murray Stahl 15,126 sh (-11.24%)
Joel Greenblatt 384,989 sh (-31.40%)
» More
Q1 2016

HOLX Guru Trades in Q1 2016

Ray Dalio 52,900 sh (New)
Paul Tudor Jones 45,242 sh (New)
Ken Fisher 47,620 sh (+0.04%)
Vanguard Health Care Fund 5,802,700 sh (unchged)
Carl Icahn Sold Out
Murray Stahl Sold Out
Kahn Brothers 1,326,484 sh (-1.76%)
RS Investment Management 924,598 sh (-19.09%)
Pioneer Investments 112,646 sh (-23.46%)
Jim Simons 1,267,918 sh (-23.95%)
Steven Cohen 557,200 sh (-44.19%)
Joel Greenblatt 19,794 sh (-94.86%)
» More
» Details

Insider Trades

Latest Guru Trades with HOLX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:NYSE:MTD, NYSE:RMD, NYSE:COO, NYSE:WAT, OTCPK:OCPNY, OTCPK:SAUHY, NAS:SIRO, NYSE:STE, NYSE:WST, OTCPK:GNGBY, NAS:XRAY, OTCPK:CLPBY, OTCPK:TRUMY, OTCPK:AHICF, NYSE:MR, NYSE:HRC, NYSE:CMN, NYSE:BCR, OTCPK:ANSLF, NAS:ICUI » details
Traded in other countries:HO1.Germany,
Hologic Inc is a developer, manufacturer and supplier of medical imaging systems and diagnostic and surgical products serving the healthcare needs of women.

Hologic Inc was incorporated in Massachusetts in October 1985 and reincorporated in Delaware in March 1990. The Company is a developer, manufacturer and supplier of medical imaging systems and diagnostic and surgical products focused on the healthcare needs of women. The Company's core business segments are focused on Breast Health, GYN surgical and Skeletal Health. The Company's breast health products include a broad portfolio of breast imaging and related products and accessories, including digital and film-based mammography systems, computer-aided detection (CAD), minimally invasive breast biopsy and tissue extraction devices, breast biopsy guidance systems, breast imaging comfort pads, and breast brachytherapy products. It has also developed a new breast imaging platform, Dimensions, which utilizes a new technology, tomosynthesis, to produce 3D images. The Company's diagnostic product offerings include the ThinPrep System used mainly for cytology applications, such as cervical cancer screening, and the Rapid Fetal Fibronectin Test for pre-term birth risk assessment. The Company's surgical product offerings include the NovaSure System, and the Adiana System. The NovaSure System enables physicians to treat women suffering from excessive menstrual bleeding in a minimally invasive manner. The Adiana System is a form of permanent female contraception intended as an alternative to tubal ligation. It sells and services its products through a combination of direct sales and service forces and a network of independent distributors and sales representatives. The Company's mammography and related products and subsystems compete with products offered by a number of competitors, including GE, Siemens, Philips, PlanMed, Agfa, Carestream Health, Fuji, IMS Giotto, Sectra and Toshiba. The manufacture, sale, lease and service of medical diagnostic and surgical devices and pharmaceutical products intended for commercial use are subject to extensive governmental regulation by the FDA in the United States and by a variety of regulatory agencies in other countries.

Top Ranked Articles about Hologic Inc

Carl Icahn Continues to Reduce Position in Hologic Guru slashes more than 3 million shares from his portfolio
Guru Carl Icahn (Trades, Portfolio) reduced his position in Hologic Inc. (NASDAQ:HOLX), slashing 3,346,767 shares from his portfolio Monday. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 47.38
HOLX's P/E(ttm) is ranked lower than
78% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.83 vs. HOLX: 47.38 )
Ranked among companies with meaningful P/E(ttm) only.
HOLX' s P/E(ttm) Range Over the Past 10 Years
Min: 25.24  Med: 62.52 Max: 470.18
Current: 47.38
25.24
470.18
Forward P/E 16.56
HOLX's Forward P/E is ranked higher than
80% of the 40 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. HOLX: 16.56 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 47.38
HOLX's PE(NRI) is ranked lower than
78% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.60 vs. HOLX: 47.38 )
Ranked among companies with meaningful PE(NRI) only.
HOLX' s PE(NRI) Range Over the Past 10 Years
Min: 25.41  Med: 61.83 Max: 446.67
Current: 47.38
25.41
446.67
Price/Owner Earnings (ttm) 18.37
HOLX's Price/Owner Earnings (ttm) is ranked higher than
75% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.97 vs. HOLX: 18.37 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
HOLX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 10.77  Med: 29.16 Max: 311.63
Current: 18.37
10.77
311.63
P/B 4.67
HOLX's P/B is ranked lower than
70% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.65 vs. HOLX: 4.67 )
Ranked among companies with meaningful P/B only.
HOLX' s P/B Range Over the Past 10 Years
Min: 0.59  Med: 2.00 Max: 9.82
Current: 4.67
0.59
9.82
P/S 3.56
HOLX's P/S is ranked lower than
63% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.58 vs. HOLX: 3.56 )
Ranked among companies with meaningful P/S only.
HOLX' s P/S Range Over the Past 10 Years
Min: 1.45  Med: 2.90 Max: 7.67
Current: 3.56
1.45
7.67
PFCF 14.30
HOLX's PFCF is ranked higher than
83% of the 82 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.65 vs. HOLX: 14.30 )
Ranked among companies with meaningful PFCF only.
HOLX' s PFCF Range Over the Past 10 Years
Min: 6.45  Med: 15.03 Max: 528.13
Current: 14.3
6.45
528.13
POCF 12.56
HOLX's POCF is ranked higher than
63% of the 104 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 14.71 vs. HOLX: 12.56 )
Ranked among companies with meaningful POCF only.
HOLX' s POCF Range Over the Past 10 Years
Min: 5.45  Med: 13.09 Max: 140.85
Current: 12.56
5.45
140.85
EV-to-EBIT 27.36
HOLX's EV-to-EBIT is ranked lower than
68% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.19 vs. HOLX: 27.36 )
Ranked among companies with meaningful EV-to-EBIT only.
HOLX' s EV-to-EBIT Range Over the Past 10 Years
Min: -137.4  Med: 30.00 Max: 153.7
Current: 27.36
-137.4
153.7
EV-to-EBITDA 13.50
HOLX's EV-to-EBITDA is ranked higher than
55% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 15.22 vs. HOLX: 13.50 )
Ranked among companies with meaningful EV-to-EBITDA only.
HOLX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -344.2  Med: 13.70 Max: 100.6
Current: 13.5
-344.2
100.6
Current Ratio 1.30
HOLX's Current Ratio is ranked lower than
83% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.51 vs. HOLX: 1.30 )
Ranked among companies with meaningful Current Ratio only.
HOLX' s Current Ratio Range Over the Past 10 Years
Min: 1.07  Med: 2.70 Max: 7.31
Current: 1.3
1.07
7.31
Quick Ratio 0.96
HOLX's Quick Ratio is ranked lower than
77% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.71 vs. HOLX: 0.96 )
Ranked among companies with meaningful Quick Ratio only.
HOLX' s Quick Ratio Range Over the Past 10 Years
Min: 0.85  Med: 2.11 Max: 6.57
Current: 0.96
0.85
6.57
Days Inventory 83.68
HOLX's Days Inventory is ranked higher than
75% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 126.38 vs. HOLX: 83.68 )
Ranked among companies with meaningful Days Inventory only.
HOLX' s Days Inventory Range Over the Past 10 Years
Min: 65.34  Med: 88.59 Max: 108.2
Current: 83.68
65.34
108.2
Days Sales Outstanding 55.38
HOLX's Days Sales Outstanding is ranked higher than
63% of the 167 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.04 vs. HOLX: 55.38 )
Ranked among companies with meaningful Days Sales Outstanding only.
HOLX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.15  Med: 63.27 Max: 85.65
Current: 55.38
56.15
85.65
Days Payable 34.25
HOLX's Days Payable is ranked lower than
73% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 54.12 vs. HOLX: 34.25 )
Ranked among companies with meaningful Days Payable only.
HOLX' s Days Payable Range Over the Past 10 Years
Min: 21.81  Med: 27.28 Max: 39.3
Current: 34.25
21.81
39.3

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.53
HOLX's Price/Projected FCF is ranked higher than
63% of the 89 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.80 vs. HOLX: 1.53 )
Ranked among companies with meaningful Price/Projected FCF only.
HOLX' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.41  Med: 1.27 Max: 12.14
Current: 1.53
0.41
12.14
Price/Median PS Value 1.22
HOLX's Price/Median PS Value is ranked lower than
61% of the 177 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.06 vs. HOLX: 1.22 )
Ranked among companies with meaningful Price/Median PS Value only.
HOLX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.15  Med: 0.87 Max: 2.57
Current: 1.22
0.15
2.57
Earnings Yield (Greenblatt) (%) 3.70
HOLX's Earnings Yield (Greenblatt) (%) is ranked higher than
59% of the 200 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.10 vs. HOLX: 3.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
HOLX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.7  Med: 2.80 Max: 7.2
Current: 3.7
0.7
7.2
Forward Rate of Return (Yacktman) (%) 26.76
HOLX's Forward Rate of Return (Yacktman) (%) is ranked higher than
88% of the 89 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.31 vs. HOLX: 26.76 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
HOLX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 0.1  Med: 6.80 Max: 72.6
Current: 26.76
0.1
72.6

More Statistics

Revenue (TTM) (Mil) $2,785
EPS (TTM) $ 0.72
Beta0.75
Short Percentage of Float2.70%
52-Week Range $31.84 - 43.00
Shares Outstanding (Mil)278.83

Analyst Estimate

Sep16 Sep17 Sep18 Sep19
Revenue (Mil $) 2,820 2,929 3,069 3,210
EPS ($) 1.91 2.11 2.38 2.75
EPS w/o NRI ($) 1.91 2.11 2.38 2.75
EPS Growth Rate
(3Y to 5Y Estimate)
9.30%
» More Articles for HOLX

Headlines

Articles On GuruFocus.com
Carl Icahn Continues to Reduce Position in Hologic Apr 07 2016 
Investment Ideas Trading With Very Low P/S Ratio Jan 13 2016 
Carl Icahn Makes Big Transactions in 3rd Quarter Jan 03 2016 
Kahn Brothers' Largest Sales During 3rd Quarter Dec 22 2015 
The Best-Performing Stocks Among Vanguard Health Care Fund's Holdings Nov 04 2015 
Amazon Among Ken Fisher's Best Performing Stocks Oct 19 2015 
Prem Watsa's Best Performing Holdings Oct 11 2015 
Carl Icahn Provides Update on Freeport-McMoRan Oct 07 2015 
Weekly 52-Week Highs Highlight: STI, GS, HOLX, MHK Jun 09 2015 
Reversing a Declining Pattern in Earnings Per Share Feb 24 2015 

More From Other Websites
Hologic, Inc. breached its 50 day moving average in a Bullish Manner : HOLX-US : June 24, 2016 Jun 24 2016
Hologic calls follow bullish momentum Jun 23 2016
Hologic’s Affirm™ Prone Biopsy System Featured at Premier Inc. Annual Innovation Celebration Jun 22 2016
Hologic: FDA Okays Procleix Zika Virus Test under IND Study Jun 22 2016
​Zika virus test by Hologic gets FDA's OK for emergency use Jun 21 2016
FDA Approves Use of the Procleix Zika Virus Assay from Hologic and Grifols to Screen the U.S. Blood... Jun 21 2016
Zika Blood Screening Test From Hologic, Grifols Gets FDA Nod Jun 20 2016
Hologic And Grifols Get FDA Approval For Procleix Zika Virus Assay Jun 20 2016
Hologic's Zika Virus Test Gets FDA Nod for Emergency Use Jun 20 2016
FDA Approves Use of the Procleix Zika Virus Assay from Hologic and Grifols to Screen the U.S. Blood... Jun 20 2016
FDA Grants Emergency Authorization for Hologic Zika Test Jun 17 2016
Hologic gets FDA 'emergency' use OK for Zika virus test Jun 17 2016
Hologic wins emergency U.S. authorization for Zika test Jun 17 2016
FDA Grants Emergency Use Authorization for Hologic's Aptima® Zika Virus Assay Jun 17 2016
KLAS Report Shows Hologic Continuing to Lead the U.S. Breast Tomosynthesis Market with Genius™ 3D... Jun 15 2016
KLAS Report Shows Hologic Continuing to Lead the U.S. Breast Tomosynthesis Market with Genius™ 3D... Jun 15 2016
How Are IHI’s Holdings’ Moving Averages Trending? Jun 14 2016
Hologic, Inc. – Value Analysis (NASDAQ:HOLX) : June 13, 2016 Jun 13 2016
Analysts Very Positive on 3 Top Stocks Following Jefferies Healthcare Conference Jun 13 2016
These 5 Stocks Are Poised for Breakouts Jun 10 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)